Home - Catalent

Skip to Main Content Skip to Footer Skip to Search

Contact Us

How can we work together

CELL & GENE THERAPY

CLINICAL SUPPLY

Latest News

Catalent and MigVax Sign Agreement to Develop an Orally Disintegrating Freeze-Dried Tablet Vaccine Against COVID-19

CATALENT LAUNCHES NEW SERVICE TO EXPEDITE DEVELOPMENT OF ORAL DRUGS

Introducing New Catalent Xpress Pharmaceutics™, a more advanced development offering to help achieve flexible and efficient First-in-Human studies and expedite development.

Explore our facilities through new 360° Virtual Site Tours and Site Tour Videos to get a window into our integrated services, superior drug delivery technologies and manufacturing solutions across the globe.

OPTIDOSE® DESIGN SOLUTION

A comprehensive drug design assessment consisting of a holistic review of the molecule, patient, and market considerations. Led by Catalent’s highly experienced team of scientific advisors, this evaluation assesses key drug design considerations that can help create more successful treatments for all stakeholders.

With our broad range of experience and deep expertise, we have the talent and unique technologies to transform your concepts into excellent results. This is backed by our global reach, with facilities located worldwide enabling us to tailor a solution to fit your needs.

SEE ALL LOCATIONS

Catalent is growing & hiring! Join the global drug development and delivery leader that puts “Patient First” at the center of our work every day. Learn more about careers at Catalent.

EXPERT CONTENT

Developing Optimized Formulations with Minimal Drug Substance

Concept to Dosing: Challenges in New Orphan Drugs

Pharmaceutical Outsourcing for Oral Development & Manufacturing

Enabling Successful Scale-Up of a Spray Drying Program

Is My Molecule Suitable for an Orally Disintegrating Tablet?

Emerging Trends and Opportunities in Orally Inhaled Drug Products